{"filings":[{"id":723961,"accession_number":"0001213900-26-062184","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2026-05-28T20:59:47+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Relmada increases authorized common shares to 200M; stockholders approve 2021 Plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized shares increased from 150M to 200M via charter amendment filed May 28, 2026.","Annual meeting held May 27: 63.5% of eligible shares voted; directors Casamento and Traversa elected.","Stockholders ratified CBIZ CPAs P.C. as auditor for FY 2026.","2021 Equity Incentive Plan amended to increase available shares by 3M to 18,052,942 total.","Proposals 1-4 all approved; no material dissent on auditor or charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":42405,"accession_number":"0001213900-26-055164","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2026-05-12T21:00:09+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Relmada reports Q1 2026 net loss of $19.1M; NDV-01 Phase 2 shows 95% CR rate; cash $234M through 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NDV-01 12-month Phase 2 in high-risk NMIBC: 95% CR at any time, 76% durable CR; BCG-unresponsive: 94% CR, 80% durable.","Cash balance $234.0M as of March 31, 2026, expected to fund operations through 2029 after $160M PIPE in March.","Net loss $19.1M ($0.22/share) vs $17.6M ($0.58) Q1 2025; R&D expense $8.1M; G&A $11.4M.","Phase 3 RESCUE registrational program on track for mid-2026; provisional patent filed April 2026 with term to 2047.","Upcoming milestones: IND filing mid-2026, initial Phase 3 data by YE 2026, Sepranolone Phase 2 in Prader-Willi mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105357,"accession_number":"0001213900-26-032403","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Relmada FY2025 net loss $57.4M; NDV-01 76% CR at 12 months; $160M PIPE closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $57.4M ($1.45/share) vs $80.0M in FY2024; Q4 net loss $19.9M ($0.27/share).","NDV-01 Phase 2: 95% CR at any time, 76% durable CR at 12 months in high-risk NMIBC; BCG-unresponsive 80% CR at 12 months.","Oversubscribed $160M PIPE closed March 2026; cash $93M at Dec 31, 2025 plus PIPE expected to fund operations through 2029.","R&D expense $26.9M (down from $46.2M); G&A $32.2M (down from $37.7M); shares outstanding 104.9M.","On track to start Phase 3 RESCUE program and Sepranolone Phase 2 in Prader-Willi mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105356,"accession_number":"0001213900-26-024918","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oversubscribed PIPE financing of ~$160M gross from 29.47M shares at $4.75/share plus pre-funded warrants, expected to close March 11, 2026.","Proceeds to be used for working capital and advancing R&D of product candidates, including NDV-01.","NDV-01 Phase 2 in high-risk NMIBC: 12-month complete response rate 76% overall, 80% in BCG-unresponsive patients.","No Grade 3+ treatment-related adverse events; no patient progressed to muscle-invasive disease or required cystectomy.","Phase 3 RESCUE program planned for mid-2026 with two registrational pathways: 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121639,"accession_number":"0001213900-25-121461","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Relmada Therapeutics amends exec employment pacts; salaries raised for CEO, COO, CFO, CAO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO salary increased to $827,176 (+5% from $787,787); other terms unchanged.","COO salary increased to $524,790 (+5% from $499,800); new severance: 12 months lump sum on non-cause termination, 18 months on CIC.","CFO salary increased to $586,940 (+5% from $558,990); new severance: 12 months lump sum on non-cause termination, 18 months on CIC.","CAO salary increased to $576,440 (+5% from $548,990); new severance: 12 months lump sum on non-cause termination, 18 months on CIC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121638,"accession_number":"0001213900-25-110088","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Relmada reports NDV-01 92% CR rate; FDA alignment for Phase 3; closes $100M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NDV-01 9-month data: 92% complete response (CR) at any time in NMIBC; 91% in BCG-unresponsive subgroup; no Grade 3 TRAEs.","FDA aligned on two Phase 3 registrational paths for NDV-01 in high-risk BCG-unresponsive and intermediate-risk NMIBC; trials start H1 2026.","Closed $100M underwritten offering of stock and pre-funded warrants on Nov 5; net ~$94M; cash runway extended into 2028.","Q3 2025 net loss $10.1M ($0.30 per share) vs $21.7M ($0.72) in Q3 2024; R&D expense fell to $4.0M from $11.1M.","Appointed Dr. Max Kates to Clinical Advisory Board; Sepranolone Phase 2 in Prader-Willi syndrome expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121637,"accession_number":"0001213900-25-106398","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Relmada prices $100M underwritten offering of common stock and pre-funded warrants at $2.20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 40.1M shares of common stock at $2.20/share and pre-funded warrants for 5.3M shares at $2.199/warrant.","Gross proceeds of ~$100M; net proceeds ~$100M after expenses, expected closing Nov 5, 2025.","Investors include Janus Henderson, Ferring Ventures, Squadron Capital, Marshall Wace, Spruce Street, OrbiMed, Columbia Threadneedle, Driehaus.","Company insiders (CEO, CFO, board members) purchasing ~$2.6M in shares at same price.","Proceeds for working capital, clinical studies, product development, and potential acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121636,"accession_number":"0001213900-25-105593","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relmada announces FDA alignment on two NDV-01 Phase III trial paths; 92% complete response rate at any time","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA supports single-arm registrational trial in refractory BCG-unresponsive NMIBC and randomized trial in intermediate-risk NMIBC.","No additional non-clinical studies required; 505(b)(2) NDA path confirmed by FDA.","92% overall CR rate at any time (23/25); 85% at 9 months; no Grade 3+ TRAEs or discontinuations.","Preliminary cash of $13.9M as of Sep 30, 2025 (unaudited).","Phase III programs targeted to start in H1 2026; follow-up Type B meetings requested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138312,"accession_number":"0001213900-25-088360","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada Therapeutics furnishes updated corporate presentation; details unavailable","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["8-K filed September 17, 2025 includes updated corporate presentation as Exhibit 99.1.","Presentation titled 'Unlocking Life Changing Therapies' but specific content not provided in filing text.","No financial or clinical data disclosed in the available filing excerpt; review full presentation for updates.","Filing under Regulation FD; information is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138311,"accession_number":"0001213900-25-087926","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Relmada regains Nasdaq minimum bid price compliance; stock remains listed on Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq written notice on Sept 15, 2025, confirming compliance with $1.00 minimum bid price rule after 10 consecutive trading days.","Compliance achieved after closing bid price exceeded $1.00 from Aug 29 to Sept 12, 2025; Nasdaq considers matter closed.","Relmada now fully compliant with all Nasdaq continued listing requirements; RLMD remains traded on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138310,"accession_number":"0001213900-25-086389","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada adds NDV-01 and sepranolone; NDV-01 Phase 2 shows 91% CR rate, Phase 3 planned 1H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added two Phase 2 candidates: NDV-01 (NMIBC) and sepranolone (Prader-Willi Syndrome/compulsivity disorders).","NDV-01 six-month Phase 2 follow-up: 91% complete response rate at any time point.","Phase 3 registrational trial for NDV-01 targeted for 1H 2026; regulatory filings and manufacturing scale-up underway.","Sepranolone Phase 2 study in PWS planned for 1H 2026; proof-of-concept data in Tourette's support.","Appointed Dr. Raj S. Pruthi as CMO–Oncology and Dr. Yair Lotan as Chair of Clinical Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138309,"accession_number":"0001213900-25-082910","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Relmada Therapeutics CMO-Urology buys 55,000 shares in open market on Aug 29, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Raj S. Pruthi, MD, Chief Medical Officer-Urology, purchased 55,000 shares of RLMD common stock on August 29, 2025.","The purchase was executed via open market transactions; no specific price disclosed in filing.","Insider purchase may signal management confidence in the company's outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138308,"accession_number":"0001213900-25-073130","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Relmada reports Q2 net loss $9.9M; NDV-01 91% overall response rate in NMIBC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $9.9M ($0.30/shr) vs $17.8M ($0.59) a year ago; R&D expense fell to $2.8M from $10.7M.","NDV-01 Phase 2: 91% complete response at any time; 90% at 6 months; no Grade 3+ TRAEs or discontinuations.","Cash $20.6M at June 30, 2025, down from $44.9M at Dec 31, 2024; shares outstanding 33.2M.","Phase 3 registration trial for NDV-01 planned for 1H 2026; Phase 2 for sepranolone in PWS in 1H 2026.","No patients progressed to muscle-invasive disease or underwent cystectomy in the study."],"consensus_eps_estimate":-0.255,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138307,"accession_number":"0001213900-25-066995","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Relmada Therapeutics gets Nasdaq transfer to Capital Market and 180-day bid-price extension","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq approved transfer to Capital Market effective July 24, 2025.","Company granted until January 19, 2026 to regain $1 minimum bid price compliance.","Must achieve closing bid price of $1.00 for 10 consecutive business days to regain compliance.","Company intends to monitor bid price and take reasonable measures to maintain listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138306,"accession_number":"0001213900-25-062803","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Relmada terminates esmethadone license agreement with Inturrisi and Manfredi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 7, 2025, Relmada delivered termination notice for the esmethadone License Agreement with Drs. Inturrisi and Manfredi.","The agreement granted exclusive worldwide license for esmethadone in psychiatric use; obligations cease 90 days after notice.","Relmada had been paying $45,000 quarterly under the agreement; upfront fee of $180,000 paid in 2018.","The termination ends Relmada's participation in the previously announced esmethadone development program.","No commercial sales, royalties, or sublicense payments had occurred under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155754,"accession_number":"0001213900-25-055334","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada appoints Dr. Raj S. Pruthi as CMO-Urology for NDV-01 NMIBC program","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Raj S. Pruthi appointed Chief Medical Officer-Urology effective June 17, 2025.","He will lead development of NDV-01, a gemcitabine/docetaxel sustained release formulation for NMIBC.","Company presented positive Phase 2 data at AUA 2025; Phase 3 trial expected to begin H1 2026.","Dr. Pruthi brings over 25 years experience in urologic oncology, including roles at enGene and J&J."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155753,"accession_number":"0001213900-25-047805","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Relmada shareholders elect director, ratify auditor, approve 2M share increase to 2021 equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held May 23, 2025; 53.6% quorum attained.","John Glasspool elected Class I director (36-month term) with 7.14M for, 2.60M withheld.","Ratification of CBIZ CPAs as auditor for FY2025 approved: 16.44M for, 0.86M against.","Amendment to 2021 Plan approved: share pool increased by 2,000,000 to 9,900,000 total.","Continuing Class II directors: Charles Casamento and Sergio Traversa; Class III: John Glasspool and Paul Kelly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155752,"accession_number":"0001213900-25-042024","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Relmada Therapeutics dismisses Marcum, appoints CBIZ CPAs as auditor after CBIZ acquisition of Marcum's attest business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum dismissed as independent auditor on May 8, 2025, following CBIZ CPAs' Nov 1, 2024 acquisition of Marcum's attest business.","CBIZ CPAs engaged as new auditor for fiscal year ending Dec 31, 2025; audit committee approved both actions.","Marcum's reports for 2024 and 2023 contained an explanatory paragraph about substantial doubt as a going concern.","No disagreements or reportable events occurred between Relmada and Marcum during the relevant periods.","Marcum furnished a letter to the SEC agreeing with the disclosures in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155751,"accession_number":"0001213900-25-035941","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relmada reports 90% ORR at any time point in Phase 2 NDV-01 trial for NMIBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["90% (18/20) achieved high-grade disease-free status at any time point; 85% ORR at 3 months.","100% complete response in CIS patients (2/2); 88.8% high-grade recurrence-free survival in papillary disease.","NDV-01 well tolerated; no treatment-related AEs >Grade 1, no discontinuations due to AEs.","Study continues enrolling; 26 patients enrolled, 20 reached 3-month assessment, 7 at 6 months.","Administration time <10 minutes; data support potential bladder-sparing outpatient therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174242,"accession_number":"0001013762-25-003432","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relmada reports FY2024 net loss $80M; cash $44.8M; new Phase 2 programs NDV-01 and sepranolone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $18.6M ($0.62/sh) vs $25.1M ($0.84/sh) in Q4 2023; FY2024 net loss $80M ($2.65/sh) vs $98.8M ($3.28/sh).","Cash and short-term investments $44.9M at Dec 31, 2024, down from $96.3M at Dec 31, 2023; runway into H1 2026 based on plans.","Topline Phase 2 data for NDV-01 (bladder cancer) expected at AUA April 26-29, 2025; Phase 2b-ready sepranolone for Tourette syndrome.","Re-evaluating further development of REL-P11 due to competitive landscape in metabolic disease.","R&D expense FY2024 $46.2M, down from $54.8M; G&A $37.7M vs $48.9M, reflecting cost-saving measures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174241,"accession_number":"0001013762-25-002786","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Relmada licenses NDV-01 from Trigone for $3.5M + 3M shares; Phase 2 data at AUA April 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront: $3.5M cash + 3,017,420 shares (10% of outstanding) for exclusive worldwide rights (ex-India, Israel, S. Africa).","Up to $200M in development/regulatory/sales milestones + 3% royalty on net sales.","NDV-01 is sustained-release gemcitabine/docetaxel for NMIBC; Phase 2 topline data at AUA April 26-29, 2025.","Shares locked up for 12 months; Trigone must vote as board recommends.","Relmada must spend ≥$5M/year on R&D/commercialization from 2026; Trigone can terminate if not."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174240,"accession_number":"0001213900-25-010711","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Relmada acquires Sepranolone for €3M; Phase 2b-ready for Tourette syndrome","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Sepranolone (GAMSA neurosteroid) from Asarina Pharma AB for €3 million; €2.756M due within 10 business days.","Phase 2a data: 28% reduction in tic severity (YGTSS, p=0.051); 69% greater quality-of-life improvement vs standard of care.","Phase 2b-ready asset for Tourette syndrome and other compulsive disorders; no CNS off-target effects in Phase 2a.","Relmada to host investor update on next development steps later in 2025.","Deal includes full global ownership rights; Asarina retains pre-closing liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174239,"accession_number":"0001213900-25-006727","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Relmada Therapeutics receives Nasdaq deficiency notice for bid price below $1; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 21, 2025, for failing minimum bid price of $1.00 for 30 consecutive business days through Jan 17, 2025.","Has until July 21, 2025 (180-day Compliance Period) to regain compliance by closing bid at $1 for at least 10 consecutive days.","May implement reverse stock split to meet bid price requirement; must complete split no later than 10 business days before deadline.","Also considering transfer of listing to Nasdaq Capital Market if unable to regain compliance on Global Market.","Listing not immediately affected; company intends to monitor and take measures to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174238,"accession_number":"0001213900-25-001249","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Relmada appoints Paul Kelly as COO; amends NEO employment agreements, suspends retention payments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Kelly named COO effective Jan 1, 2025; salary $476K, target bonus 40%, severance 6 months.","Amended employment agreements for CEO Traversa, CFO Shenouda, CAO Ence extend option exercisability upon termination.","NEOs receive no salary increases for FY2025, no cash bonuses or long-term incentive awards for FY2024.","All further retention payments for NEOs and Kelly suspended until Board approves strategic initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191171,"accession_number":"0001213900-24-106646","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada halts REL-1017 Phase 3 trials after DMC review; begins strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinues Reliance II and Relight Phase 3 studies for major depressive disorder candidate REL-1017.","Decision follows data monitoring committee evaluation of full Reliance II dataset.","Will continue advancing Phase 1 study of REL-P11, a metabolic disease investigational agent.","Commenced process to explore strategic alternatives including sale, merger, or asset acquisition.","Engaging financial advisor; no timetable set for completion of strategic review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191170,"accession_number":"0001213900-24-105245","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada Phase 3 Reliance II trial for REL-1017 in MDD deemed futile at interim analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DMC interim analysis indicates Reliance II is futile, unlikely to meet primary efficacy endpoint with statistical significance.","No new safety signals reported; DMC did not identify any safety concerns.","Relmada to evaluate next steps for REL-1017 program; continues development of REL-P11 for metabolic disease.","Cash and cash equivalents ~$54.1M as of Sep 30, 2024, providing runway.","Sergio Traversa, CEO, expressed disappointment and gratitude to participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225111,"accession_number":"0001213900-24-047968","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Relmada shareholders reject equity plan increase and say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director John Glasspool received 7.7M for and 9.98M withheld; Paul Kelly had 11.8M for, 5.88M withheld.","Ratification of Marcum LLP as auditor approved: 19.98M for, 1.97M against.","Proposal to increase 2021 Equity Plan by 4.5M shares failed: 4.26M for, 13.41M against.","Advisory vote on executive compensation did not pass: 7.53M for, 10.12M against.","72.9% of outstanding shares (21.99M of 30.17M) were present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244337,"accession_number":"0001213900-24-024022","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relmada reports FY 2023 net loss of $98.8M; advancing Phase 3 MDD trials with data expected H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $25.2M ($0.84/share) vs $37.9M ($1.28) in Q4 2022; full-year net loss $98.8M ($3.28/share).","Cash, equivalents and short-term investments at Dec 31, 2023: $96.3M, down from $148.3M a year earlier.","R&D expense fell to $54.8M in FY 2023 from $113.3M in FY 2022, reflecting completion of prior Phase 3 trials.","REL-1017 Phase 3 Reliance II enrollment on track; top-line data expected H2 2024; Relight enrollment targeted by year-end 2024.","REL-P11 psilocybin Phase 1 in obese patients expected H1 2024; Phase 2a proof-of-concept data seen H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244336,"accession_number":"0001213900-24-003000","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Relmada Therapeutics CMO Cedric O'Gorman departs; separation agreement includes $414,500 payment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cedric O'Gorman's service as Chief Medical Officer ended January 3, 2024, by mutual agreement.","Separation agreement provides $414,500 payment and six months of COBRA premium coverage.","O'Gorman may exercise vested stock options under the 2021 Equity Incentive Plan until March 3, 2024, via cashless exercise.","Agreement includes confidentiality, release, and non-disparagement provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244335,"accession_number":"0001213900-24-000999","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada provides 2024 outlook: REL-1017 study 302 ~50% enrolled; psilocybin Phase 1 planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REL-1017 Phase 3 study 302 (Reliance II) is approximately 50% enrolled (target ~300 patients); full enrollment expected H1 2024.","REL-1017 Phase 3 study 304 (Relight) enrollment to complete by year-end 2024, also ~300 patients.","Phase 1 trial of modified-release psilocybin (REL-P11) in obese patients with steatotic liver disease to start H1 2024; Phase 2a data expected H1 2025.","Dr. Cedric O'Gorman steps down as CMO; Dr. Andrew Cutler appointed Senior Clinical Development Advisor to support NDA process.","Cash runway expected to extend beyond all 2024 catalysts; no specific cash balance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244334,"accession_number":"0001213900-24-000858","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Relmada Therapeutics CMO Cedric O'Gorman departs effective Jan 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cedric O'Gorman concluded his role as Chief Medical Officer on January 3, 2024, by mutual agreement.","No successor or interim CMO has been announced by the company.","CMO departure creates uncertainty for Relmada's clinical development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261751,"accession_number":"0001213900-23-084735","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relmada reports Q3 net loss $22.0M; cash $106.3M; REL-1017 Phase 3 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $22.0M ($0.73/share) vs $39.4M ($1.31) YoY.","R&D expense $10.5M, down from $30.5M due to Reliance I/III completion.","Cash and equivalents $106.3M at Sep 30, 2023 vs $148.3M at Dec 31, 2022.","Phase 3 REL-1017 trials for MDD: Reliance II enrollment on track for H1 2024; Relight for H2 2024.","Psilocybin program: Phase 1 in steatotic liver disease to start early 2024, Phase 2a planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261750,"accession_number":"0001013762-23-002985","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada reports positive preclinical psilocybin data for MASLD; Phase 1 in early 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Low-dose psilocybin (0.05 mg/kg, daily oral) in HFHFD mice reduced liver steatosis, body weight (12% reduction), and fasting blood glucose (p<0.05).","Mechanism involves 5-HT-2A receptor agonism, distinct from GLP-1 agents; restored plasma/liver triglyceride levels to normal-diet levels.","Company to initiate single-ascending dose Phase 1 trial in obese MASLD patients in early 2024.","Data to be presented at AASLD The Liver Meeting 2023 (Nov 10-14, 2023, Boston)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261749,"accession_number":"0001013762-23-002900","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Relmada Therapeutics updates corporate presentation on CNS pipeline","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed corporate presentation dated October 10, 2023 as Exhibit 99.1.","No specific financial or clinical data disclosed in the 8-K filing.","Presentation title: 'Targeting Major Advances in the Treatment of CNS Disorders'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261748,"accession_number":"0001013762-23-001391","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Relmada Therapeutics updates corporate presentation on October 4, 2023","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated corporate presentation under Item 8.01; no financial or pipeline data disclosed.","Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders'.","No material changes or specific business updates provided in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278950,"accession_number":"0001213900-23-078049","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relmada reports Phase 3 open-label data for REL-1017 in MDD: rapid, sustained symptom improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 204 de novo patients, mean MADRS total score improved 11.3 points at Day 7 and 22.5 points at Month 12.","Clinical response (≥50% MADRS improvement) achieved by 26.6% at Day 7 and 77.2% at Month 12.","Remission (MADRS ≤10) rates were 12.1% at Day 7 and 54.4% at Month 12.","Safety: ~3% discontinuation due to AEs; no new safety signals; common AEs were headache (4.4%), nausea (4.0%), dizziness (2.4%).","Functional impairment (SDS) improved ~50% by Month 6 in de novo patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278949,"accession_number":"0001213900-23-074165","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Board member Eric Schmidt resigns; cites compliance for new sell-side analyst role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Schmidt resigned from the Board effective September 5, 2023, with no disagreement with the company or management.","Resignation due to compliance requirements from his new role as a sell-side equity analyst at a Wall Street investment banking firm.","Schmidt served as a Class I director since 2019, chaired the Audit Committee, and was on the Governance Committee.","No replacement has been announced for the vacant board position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278948,"accession_number":"0001213900-23-065674","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Relmada Therapeutics updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed updated corporate presentation as Exhibit 99.1 on August 10, 2023.","Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders'.","Filing does not include specific new financial results, guidance, or milestones.","No material changes to corporate strategy or pipeline disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278947,"accession_number":"0001213900-23-064577","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relmada Q2 net loss narrows; Phase 3 MDD trials on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.3M ($0.84/share) vs $39.9M ($1.33) in Q2 2022; R&D expense down to $13.7M from $30.9M.","Cash and short-term investments $118.5M at June 30; company says sufficiently funded for Phase 3 readouts in 2024.","Phase 3 Reliance II (302) enrollment ongoing; Relight (304) screening started; both expected to complete in 2024.","One-year open-label safety study (Reliance-OLS) completed; data expected later in the current quarter.","Human abuse potential data for REL-1017 published in peer-reviewed Translational Psychiatry."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297257,"accession_number":"0001213900-23-043101","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Relmada Therapeutics stockholders approve plan amendment and elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 2,500,000 to 7,900,000.","Charles J. Casamento and Sergio Traversa elected as Class II directors with 10,159,479 and 17,003,403 votes respectively.","Ratification of Marcum LLP as independent auditor for fiscal 2023 approved with 22,048,083 votes.","Approximately 76.9% of eligible common stock voted at the annual meeting held on May 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297256,"accession_number":"0001213900-23-040004","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Relmada provides Phase 3 update for REL-1017 in MDD; cash $132.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $132.4M as of 3/31/23; ~30.1M common shares outstanding (45.6M as-converted).","Reliance I and III did not meet primary endpoints; post-hoc analysis with removal of two sites showed -4.1 MADRS difference (p=0.02).","Key trial improvements: require medical records to verify depression, limit patients per site, simplify assessments.","Upcoming milestones: complete Reliance II (adjunctive) in 1H 2024; initiate additional Phase 3 adjunctive trial mid-2023, completion 2H 2024.","No serious treatment-related TEAEs, no abuse potential; safety profile consistent across studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297255,"accession_number":"0001213900-23-038577","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relmada Therapeutics reports Q1 2023 net loss of $26.3M; provides REL-1017 trial update","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.3M ($0.87 per share) vs $39.7M ($1.40) in Q1 2022.","R&D expense fell to $15.9M from $25.0M, driven by completion of RELIANCE I and III studies.","Cash, cash equivalents, and short-term investments of $132.4M as of March 31, 2023.","Enrollment ongoing in Phase 3 Study 302 (REL-1017 for MDD); completion expected H1 2024.","New Phase 3 Study 304 to start mid-2023 with ~300 patients; completion anticipated H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297254,"accession_number":"0001213900-23-030851","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Relmada Therapeutics updates corporate presentation, no financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed 8-K on April 19, 2023, to announce an updated corporate presentation.","Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders' filed as Exhibit 99.1.","No specific financial or operational milestones provided in the filing or exhibit text.","CEO Sergio Traversa signed the filing; presentation may contain pipeline or strategy updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317628,"accession_number":"0001213900-23-022428","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relmada Q4 net loss $37.9M; cash at $148.3M; plans revised REL-1017 MDD trials after Study 301 failure","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $37.9M ($1.28/diluted share), vs $34.4M ($1.80) in Q4 2021; full-year net loss $157.0M.","Cash and short-term investments $148.3M at Dec 31, 2022, down from $211.9M a year earlier.","Will amend ongoing Phase 3 Study 302 and initiate new Study 304 for REL-1017 as adjunctive MDD treatment.","Appointed Cedric O'Gorman, M.D. as CMO and Fabiana Fedeli as independent board director.","Study 302 enrollment expected H1 2024; Study 304 to start mid-2023 with data in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317627,"accession_number":"0001213900-23-019392","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Relmada confirms no cash or securities held at Silicon Valley Bank","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company discloses under Regulation FD that it holds no deposits or securities at SVB.","Disclosure addresses investor concerns amid SVB's collapse in March 2023.","No financial exposure or impact from SVB failure; business as usual."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317626,"accession_number":"0001213900-23-002865","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-01-17T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Relmada Therapeutics appoints Fabiana Fedeli to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 5 to 6 members; Fedeli appointed Class I director effective Jan 12, 2023.","Annual cash compensation: $66k as director, $9.9k audit committee, $7.7k compensation committee.","Granted option to buy 200,000 shares at $4.22, vesting over 4 years, subject to shareholder approval.","Fedeli is Chief Investment Officer at M&G Investments and was named in Financial News' 100 Most Influential Women in Finance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317625,"accession_number":"0001213900-23-001518","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relmada Therapeutics appoints Cedric O'Gorman MD as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. O'Gorman appointed CMO effective January 9, 2023, leading medical, clinical, and regulatory for REL-1017 MDD program.","He brings over 20 years CNS experience; previously CMO at Alpha Cognition and SVP at Axsome Therapeutics.","CEO cites his expertise with similar-mechanism antidepressants and key regulatory discussions ahead.","Corporate presentation updated and filed as Exhibit 99.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317624,"accession_number":"0001213900-23-001162","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Relmada Therapeutics engages director Paul Kelly as special advisor at $32k/mo; Kelly loses independent director status","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Kelly, a director, entered Advisory Agreement as Special Advisor to CEO effective Jan 1, 2023, with $32,000 monthly fee.","Kelly will no longer be considered independent director; he resigns from Audit and Compensation Committees.","Charles J. Casamento appointed Chairman of Compensation Committee effective Jan 1, 2023.","Agreement term of one year, renewable automatically; early termination with 30 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335860,"accession_number":"0001213900-22-083290","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2022-12-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Relmada extends key man provisions in esmethadone license to Dec 31, 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 extends the 'Key Man' termination-protection period from Dec 31, 2022 to Dec 31, 2027.","Licensor may terminate license if CEO Sergio Traversa is fired without cause or his role is materially reduced.","License covers esmethadone (REL-1017) for psychiatric use; no other terms of the license were changed.","Extension locks in CEO-linked protections for an additional five years through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335859,"accession_number":"0001213900-22-078255","cik":1553643,"company_name":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relmada phase 3 RELIANCE I trial for REL-1017 fails primary endpoint; post-hoc analysis shows significance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RELIANCE I did not achieve statistical significance on MADRS at Day 28: REL-1017 -15.1 vs placebo -12.9 (2.2-point difference).","Response rate statistically significant: 39.8% REL-1017 vs 27.2% placebo (p<0.05).","Post-hoc analysis excluding two high-enrolling centers with implausible placebo response showed 4.1-point MADRS difference (p=0.02).","Safety profile favorable: no opioid-like, withdrawal, or psychotomimetic effects; no QTcF prolongation.","Company is applying protocol and operational changes to the ongoing RELIANCE II trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":760978629.8422865,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-07T23:59:59+00:00|335859"}